Chiralix 2015
2025-08-24
Chiralix 2015
金山科研平台代理微信：jinshanbioChiralix代理，Chiralix中国代理，Chiralix上海代理，Chiralix总代，ChiralixChiralix专业代理-金山科研平台，具体产品信息欢迎电询
Chiralix是一家专业从事手性有机分子合成和供应的公司，我们致力于制药公司及生命科学研究领域的实验室研究用*手性分子的生产和研发。我们集良好的有机分子合成、过渡金属催化、生物催化技术于一身，具备灵活与高效的多种手性分子合成工艺，如基团的氨基酸，叠氮酸，氨基醇及多种肽段模块。除了提供大量的手性分子成品，我们还提供优质的研发服务，如复杂有机分子的合成等。
产品列表
| 货号 | 品名 | 化学名 | CAS号 | 分子量 | 分子式 | Synonyms | 纯度 | 包装 | 价格 | 品牌 |
| CX90418-1G | L-allysineethyleneacetal | (S)-2-amino-5-(1,3-dioxolan-2-yl)-pentanoicacid | 215054-80-1 | 189.21 | C8H15NO4 | H-Aea-OH | 99% | 1G | 6200 | chiralix |
| CX90418-2G | L-allysineethyleneacetal | (S)-2-amino-5-(1,3-dioxolan-2-yl)-pentanoicacid | 215054-80-1 | 189.21 | C8H15NO4 | H-Aea-OH | 99% | 2G | 10600 | chiralix |
| CX90418-5G | L-allysineethyleneacetal | (S)-2-amino-5-(1,3-dioxolan-2-yl)-pentanoicacid | 215054-80-1 | 189.21 | C8H15NO4 | H-Aea-OH | 99% | 5G | 19900 | chiralix |
| CX60325-200MG | D-homopropargylglycine | (R)-2-aminohex-5-ynoicacid | 211054-02-3 | 127.14 | C6H9NO2 | H-D-Hpg-OH | >98% | 200MG | 4800 | chiralix |
| CX60325-500MG | D-homopropargylglycine | (R)-2-aminohex-5-ynoicacid | 211054-02-3 | 127.14 | C6H9NO2 | H-D-Hpg-OH | >98% | 500MG | 9800 | chiralix |
| CX60325-1G | D-homopropargylglycine | (R)-2-aminohex-5-ynoicacid | 211054-02-3 | 127.14 | C6H9NO2 | H-D-Hpg-OH | >98% | 1G | 16000 | chiralix |
| CX80065-500MG | Fmoc-L-homopropargylglycine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hex-5-ynoicacid | 942518-21-0 | 349.38 | C21H19NO4 | Fmoc-Hpg-OH | >97% | 500MG | 11200 | chiralix |
| CX80065-1G | Fmoc-L-homopropargylglycine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hex-5-ynoicacid | 942518-21-0 | 349.38 | C21H19NO4 | Fmoc-Hpg-OH | >97% | 1G | 18400 | chiralix |
| CX90138-200MG | L-homopropargylglycine | (S)-2-aminohex-5-ynoicacid | 98891-36-2 | 127.14 | C6H9NO2 | H-Hpg-OH | >98% | 200MG | 4800 | chiralix |
| CX90138-500MG | L-homopropargylglycine | (S)-2-aminohex-5-ynoicacid | 98891-36-2 | 127.14 | C6H9NO2 | H-Hpg-OH | >98% | 500MG | 9800 | chiralix |
| CX90138-1G | L-homopropargylglycine | (S)-2-aminohex-5-ynoicacid | 98891-36-2 | 127.14 | C6H9NO2 | H-Hpg-OH | >98% | 1G | 16000 | chiralix |
| CX56292-500MG | (3R,4R)-3,4-dihydroxycyclohexa-1,5-diene-1-carboxylicacid | (3R,4R)-3,4-dihydroxycyclohexa-1,5-diene-1-carboxylicacid | 108646-25-9 | 156.14 | C7H8O4 | >97% | 500MG | 6000 | chiralix | |
| CX56292-1G | (3R,4R)-3,4-dihydroxycyclohexa-1,5-diene-1-carboxylicacid | (3R,4R)-3,4-dihydroxycyclohexa-1,5-diene-1-carboxylicacid | 108646-25-9 | 156.14 | C7H8O4 | >97% | 1G | 9800 | chiralix | |
| CX24022-500MG | (5S,6S)-6-amino-5-hydroxycyclohexa-1,3-dienecarboxylicacid | (5S,6S)-6-amino-5-hydroxycyclohexa-1,3-dienecarboxylicacid | 38127-17-2 | 155.15 | C7H9NO3 | >98% | 500MG | 6000 | chiralix | |
| CX24022-1G | (5S,6S)-6-amino-5-hydroxycyclohexa-1,3-dienecarboxylicacid | (5S,6S)-6-amino-5-hydroxycyclohexa-1,3-dienecarboxylicacid | 38127-17-2 | 155.15 | C7H9NO3 | >98% | 1G | 9800 | chiralix | |
| CX41399-1G | (S)-beta3-phenylalanine | (S)-3-amino-3-phenylpropanoicacid | 40856-44-8 | 165.19 | C9H11NO2 | 99% | 1G | 2200 | chiralix | |
| CX41399-2G | (S)-beta3-phenylalanine | (S)-3-amino-3-phenylpropanoicacid | 40856-44-8 | 165.19 | C9H11NO2 | 99% | 2G | 3800 | chiralix | |
| CX41399-5G | (S)-beta3-phenylalanine | (S)-3-amino-3-phenylpropanoicacid | 40856-44-8 | 165.19 | C9H11NO2 | 99% | 5G | 7200 | chiralix | |
| CX64691-1G | D-tert-leucine | (R)-2-amino-3,3-dimethylbutyricacid | 26782-71-8 | 131.17 | C6H13NO2 | H-D-tert-Leu-OH | 99% | 1G | 2200 | chiralix |
| CX64691-2G | D-tert-leucine | (R)-2-amino-3,3-dimethylbutyricacid | 26782-71-8 | 131.17 | C6H13NO2 | H-D-tert-Leu-OH | 99% | 2G | 3800 | chiralix |
| CX64691-5G | D-tert-leucine | (R)-2-amino-3,3-dimethylbutyricacid | 26782-71-8 | 131.17 | C6H13NO2 | H-D-tert-Leu-OH | 99% | 5G | 7200 | chiralix |
| CX97471-500MG | (S)-alpha-methyl-phenylglycine | (S)-2-amino-2-phenylpropanoicacid | 13398-26-0 | 165.19 | C9H11NO2 | (S)-H-Mpg-OH | >98% | 500MG | 5200 | chiralix |
| CX97471-1G | (S)-alpha-methyl-phenylglycine | (S)-2-amino-2-phenylpropanoicacid | 13398-26-0 | 165.19 | C9H11NO2 | (S)-H-Mpg-OH | >98% | 1G | 9000 | chiralix |
| CX97471-2G | (S)-alpha-methyl-phenylglycine | (S)-2-amino-2-phenylpropanoicacid | 13398-26-0 | 165.19 | C9H11NO2 | (S)-H-Mpg-OH | >98% | 2G | 14800 | chiralix |
| CX58692-1G | (S)-allylglycinolhydrochloride | (S)-2-aminopent-4-en-1-olhydrochloride | 926660-03-9 | 137.61 | C5H12ClNO | >98% | 1G | 7400 | chiralix | |
| CX58692-2G | (S)-allylglycinolhydrochloride | (S)-2-aminopent-4-en-1-olhydrochloride | 926660-03-9 | 137.61 | C5H12ClNO | >98% | 2G | 12800 | chiralix | |
| CX40529-1G | (S)-propargylglycinolhydrochloride | (S)-2-aminopent-4-yn-1-olhydrochloride | Notavailable | 135.59 | C5H10ClNO | >98% | 1G | 8200 | chiralix | |
| CX40529-2G | (S)-propargylglycinolhydrochloride | (S)-2-aminopent-4-yn-1-olhydrochloride | Notavailable | 135.59 | C5H10ClNO | >98% | 2G | 14000 | chiralix | |
| CX80916-500MG | bis(N-Cbz)-2-deoxystreptamine | benzyl4,5,6-trihydroxycyclohexane-1,3-diyldicarbamate | 6216-32-6 | 430.45 | C22H26N2O7 | bis-Z-2-DOS | >95% | 500MG | 6200 | chiralix |
| CX80916-1G | bis(N-Cbz)-2-deoxystreptamine | benzyl4,5,6-trihydroxycyclohexane-1,3-diyldicarbamate | 6216-32-6 | 430.45 | C22H26N2O7 | bis-Z-2-DOS | >95% | 1G | 10800 | chiralix |
| CX93851-100MG | (2S,5R)-5-hydroxypipecolicacidhydrochloride | (2S,5R)-5-hydroxypiperidine-2-carboxylicacidhydrochloride | 824943-40-0 | 181.62 | C6H12ClNO3 | >98% | 100MG | 3800 | chiralix | |
| CX93851-500MG | (2S,5R)-5-hydroxypipecolicacidhydrochloride | (2S,5R)-5-hydroxypiperidine-2-carboxylicacidhydrochloride | 824943-40-0 | 181.62 | C6H12ClNO3 | >98% | 500MG | 12600 | chiralix | |
| CX93851-1G | (2S,5R)-5-hydroxypipecolicacidhydrochloride | (2S,5R)-5-hydroxypiperidine-2-carboxylicacidhydrochloride | 824943-40-0 | 181.62 | C6H12ClNO3 | >98% | 1G | 19600 | chiralix | |
| CX19922-1G | (S)-beta3-phenylalaninemethylesterhydrochloride | (S)-methyl3-amino-3-phenylpropanoatehydrochloride | 144494-72-4 | 215.68 | C10H14ClNO2 | >98% | 1G | 3000 | chiralix | |
| CX19922-2G | (S)-beta3-phenylalaninemethylesterhydrochloride | (S)-methyl3-amino-3-phenylpropanoatehydrochloride | 144494-72-4 | 215.68 | C10H14ClNO2 | >98% | 2G | 5200 | chiralix | |
| CX19922-5G | (S)-beta3-phenylalaninemethylesterhydrochloride | (S)-methyl3-amino-3-phenylpropanoatehydrochloride | 144494-72-4 | 215.68 | C10H14ClNO2 | >98% | 5G | 9800 | chiralix | |
| CX62577-10MG | 6,8a-diepi-castanospermine | (1S,6R,7R,8R,8aS)-octahydroindolizine-1,6,7,8-tetraol | 106798-21-0 | 189.21 | C8H15NO4 | >98% | 10MG | 3600 | chiralix | |
| CX62577-50MG | 6,8a-diepi-castanospermine | (1S,6R,7R,8R,8aS)-octahydroindolizine-1,6,7,8-tetraol | 106798-21-0 | 189.21 | C8H15NO4 | >98% | 50MG | 11800 | chiralix | |
| CX25404-1G | Fmoc-L-azidoornithine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-azidopentanoicacid | 1097192-04-5 | 380.40 | C20H20N4O4 | Fmoc-Orn(N2)-OH | >98% | 1G | 3400 | chiralix |
| CX25404-5G | Fmoc-L-azidoornithine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-azidopentanoicacid | 1097192-04-5 | 380.40 | C20H20N4O4 | Fmoc-Orn(N2)-OH | >98% | 5G | 12000 | chiralix |
| CX23880-5MG | rac-GR24 | (3aR*,8bS*,E)-3-(((R*)-4-methyl-5-oxo-2,5-dihydrofuran-2-yloxy)methylene)-3,3a,4,8b-tetrahydro-2H-inde,2-b]furan-2-one | 76974-79-3 | 298.29 | C17H14O5 | >98% | 5MG | 5000 | chiralix | |
| CX23880-20MG | rac-GR24 | (3aR*,8bS*,E)-3-(((R*)-4-methyl-5-oxo-2,5-dihydrofuran-2-yloxy)methylene)-3,3a,4,8b-tetrahydro-2H-inde,2-b]furan-2-one | 76974-79-3 | 298.29 | C17H14O5 | >98% | 20MG | 15000 | chiralix | |
| CX23880-100MG | rac-GR24 | (3aR*,8bS*,E)-3-(((R*)-4-methyl-5-oxo-2,5-dihydrofuran-2-yloxy)methylene)-3,3a,4,8b-tetrahydro-2H-inde,2-b]furan-2-one | 76974-79-3 | 298.29 | C17H14O5 | >98% | 100MG | 35000 | chiralix | |
| CX38605-1G | Fmoc-L-allysineethyleneacetal | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(1,3-dioxolan-2-yl)pentanoicacid | Notavailable | 411.45 | C23H25NO6 | Fmoc-Aea-OH | >97% | 1G | 7200 | chiralix |
| CX38605-2G | Fmoc-L-allysineethyleneacetal | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(1,3-dioxolan-2-yl)pentanoicacid | Notavailable | 411.45 | C23H25NO6 | Fmoc-Aea-OH | >97% | 2G | 12400 | chiralix |
| CX59650-1G | Fmoc-L-azidohomoalanine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-azidobutanoicacid | 942518-20-9 | 366.37 | C19H18N4O4 | Fmoc-Azh-OH | >98% | 1G | 3400 | chiralix |
| CX59650-5G | Fmoc-L-azidohomoalanine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-azidobutanoicacid | 942518-20-9 | 366.37 | C19H18N4O4 | Fmoc-Azh-OH | >98% | 5G | 12000 | chiralix |
| CX94894-200MG | L-bishomopropargylglycine | (S)-2-aminohept-6-ynoicacid | 835627-45-7 | 141.17 | C7H11NO2 | H-Bpg-OH | >98% | 200MG | 4400 | chiralix |
| CX94894-500MG | L-bishomopropargylglycine | (S)-2-aminohept-6-ynoicacid | 835627-45-7 | 141.17 | C7H11NO2 | H-Bpg-OH | >98% | 500MG | 9000 | chiralix |
| CX94894-1G | L-bishomopropargylglycine | (S)-2-aminohept-6-ynoicacid | 835627-45-7 | 141.17 | C7H11NO2 | H-Bpg-OH | >98% | 1G | 14600 | chiralix |
| CX13745-1G | (R)-propargylglycinolhydrochloride | (R)-2-aminopent-4-yn-1-olhydrochloride | Notavailable | 135.59 | C5H10ClNO | >98% | 1G | 8200 | chiralix | |
| CX13745-2G | (R)-propargylglycinolhydrochloride | (R)-2-aminopent-4-yn-1-olhydrochloride | Notavailable | 135.59 | C5H10ClNO | >98% | 2G | 14000 | chiralix | |
| CX78500-1G | (R)-allylglycinolhydrochloride | (R)-2-aminopent-4-en-1-olhydrochloride | 926660-30-2 | 137.61 | C5H12ClNO | >98% | 1G | 7400 | chiralix | |
| CX78500-2G | (R)-allylglycinolhydrochloride | (R)-2-aminopent-4-en-1-olhydrochloride | 926660-30-2 | 137.61 | C5H12ClNO | >98% | 2G | 12800 | chiralix | |
| CX69324-500MG | bis(N-Boc)-2-deoxystreptamine | tert-butyl(1R,3S,4R,5r,6S)-4,5,6-trihydroxycyclohexane-1,3-diyldicarbamate | 189157-45-7 | 362.42 | C16H30N2O7 | bis-Boc-2-DOS | >95% | 500MG | 6200 | chiralix |
| CX69324-1G | bis(N-Boc)-2-deoxystreptamine | tert-butyl(1R,3S,4R,5r,6S)-4,5,6-trihydroxycyclohexane-1,3-diyldicarbamate | 189157-45-7 | 362.42 | C16H30N2O7 | bis-Boc-2-DOS | >95% | 1G | 10800 | chiralix |
| CX96388-1G | Boc-L-allysineethyleneacetal | (S)-2-(tert-butoxycarbonylamino)-5-(1,3-dioxolan-2-yl)pentanoicacid | Notavailable | 289.32 | C13H23NO6 | Boc-Aea-OH | >98% | 1G | 6200 | chiralix |
| CX96388-2G | Boc-L-allysineethyleneacetal | (S)-2-(tert-butoxycarbonylamino)-5-(1,3-dioxolan-2-yl)pentanoicacid | Notavailable | 289.32 | C13H23NO6 | Boc-Aea-OH | >98% | 2G | 10600 | chiralix |
| CX96388-5G | Boc-L-allysineethyleneacetal | (S)-2-(tert-butoxycarbonylamino)-5-(1,3-dioxolan-2-yl)pentanoicacid | Notavailable | 289.32 | C13H23NO6 | Boc-Aea-OH | >98% | 5G | 19900 | chiralix |
| CX42388-1G | Cbz-L-allysineethyleneacetal | (S)-2-(benzyloxycarbonylamino)-5-(1,3-dioxolan-2-yl)pentanoicacid | 852822-01-6 | 323.34 | C16H21NO6 | Z-Aea-OH | >98% | 1G | 6200 | chiralix |
| CX42388-2G | Cbz-L-allysineethyleneacetal | (S)-2-(benzyloxycarbonylamino)-5-(1,3-dioxolan-2-yl)pentanoicacid | 852822-01-6 | 323.34 | C16H21NO6 | Z-Aea-OH | >98% | 2G | 10600 | chiralix |
| CX42388-5G | Cbz-L-allysineethyleneacetal | (S)-2-(benzyloxycarbonylamino)-5-(1,3-dioxolan-2-yl)pentanoicacid | 852822-01-6 | 323.34 | C16H21NO6 | Z-Aea-OH | >98% | 5G | 19900 | chiralix |
| CX44656-500MG | Boc-L-homopropargylglycine | (S)-2-(tert-butoxycarbonylamino)hex-5-ynoicacid | 208522-16-1 | 227.26 | C11H17NO4 | Boc-Hpg-OH | >98% | 500MG | 9800 | chiralix |
| CX44656-1G | Boc-L-homopropargylglycine | (S)-2-(tert-butoxycarbonylamino)hex-5-ynoicacid | 208522-16-1 | 227.26 | C11H17NO4 | Boc-Hpg-OH | >98% | 1G | 16000 | chiralix |
| CX69013-500MG | Cbz-L-homopropargylglycine | (S)-2-(benzyloxycarbonylamino)hex-5-ynoicacid | Notavailable | 261.27 | C14H15NO4 | Z-Hpg-OH | >98% | 500MG | 9800 | chiralix |
| CX69013-1G | Cbz-L-homopropargylglycine | (S)-2-(benzyloxycarbonylamino)hex-5-ynoicacid | Notavailable | 261.27 | C14H15NO4 | Z-Hpg-OH | >98% | 1G | 16000 | chiralix |
| CX54783-500MG | Boc-D-homopropargylglycine | (R)-2-(tert-butoxycarbonylamino)hex-5-ynoicacid | Notavailable | 227.26 | C11H17NO4 | Boc-D-Hpg-OH | >98% | 500MG | 9800 | chiralix |
| CX54783-1G | Boc-D-homopropargylglycine | (R)-2-(tert-butoxycarbonylamino)hex-5-ynoicacid | Notavailable | 227.26 | C11H17NO4 | Boc-D-Hpg-OH | >98% | 1G | 16000 | chiralix |
| CX14845-500MG | Cbz-D-homopropargylglycine | (R)-2-(benzyloxycarbonylamino)hex-5-ynoicacid | Notavailable | 261.27 | C14H15NO4 | Z-D-Hpg-OH | >98% | 500MG | 9800 | chiralix |
| CX14845-1G | Cbz-D-homopropargylglycine | (R)-2-(benzyloxycarbonylamino)hex-5-ynoicacid | Notavailable | 261.27 | C14H15NO4 | Z-D-Hpg-OH | >98% | 1G | 16000 | chiralix |
| CX87818-500MG | Fmoc-D-homopropargylglycine | (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hex-5-ynoicacid | Notavailable | 349.38 | C21H19NO4 | Fmoc-D-Hpg-OH | >97% | 500MG | 11200 | chiralix |
| CX87818-1G | Fmoc-D-homopropargylglycine | (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hex-5-ynoicacid | Notavailable | 349.38 | C21H19NO4 | Fmoc-D-Hpg-OH | >97% | 1G | 18400 | chiralix |
| CX57816-500MG | Fmoc-L-bishomopropargylglycine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hept-6-ynoicacid | Notavailable | 363.41 | C22H21NO4 | Fmoc-Bpg-OH | >97% | 500MG | 10400 | chiralix |
| CX57816-1G | Fmoc-L-bishomopropargylglycine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hept-6-ynoicacid | Notavailable | 363.41 | C22H21NO4 | Fmoc-Bpg-OH | >97% | 1G | 16800 | chiralix |
| CX32424-200MG | D-bishomopropargylglycine | (R)-2-aminohept-6-ynoicacid | 211054-03-4 | 141.17 | C7H11NO2 | H-D-Bpg-OH | >98% | 200MG | 4400 | chiralix |
| CX32424-500MG | D-bishomopropargylglycine | (R)-2-aminohept-6-ynoicacid | 211054-03-4 | 141.17 | C7H11NO2 | H-D-Bpg-OH | >98% | 500MG | 9000 | chiralix |
| CX32424-1G | D-bishomopropargylglycine | (R)-2-aminohept-6-ynoicacid | 211054-03-4 | 141.17 | C7H11NO2 | H-D-Bpg-OH | >98% | 1G | 14600 | chiralix |
| CX80846-500MG | Fmoc-D-bishomopropargylglycine | (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hept-6-ynoicacid | Notavailable | 363.41 | C22H21NO4 | Fmoc-D-Bpg-OH | >97% | 500MG | 10400 | chiralix |
| CX80846-1G | Fmoc-D-bishomopropargylglycine | (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hept-6-ynoicacid | Notavailable | 363.41 | C22H21NO4 | Fmoc-D-Bpg-OH | >97% | 1G | 16800 | chiralix |
| CX52977-1G | (S)-Boc-beta3-phenylalanine | (S)-3-(tert-butoxycarbonylamino)-3-phenylpropanoicacid | 103365-47-5 | 265.30 | C14H19NO4 | >98% | 1G | 2200 | chiralix | |
| CX52977-2G | (S)-Boc-beta3-phenylalanine | (S)-3-(tert-butoxycarbonylamino)-3-phenylpropanoicacid | 103365-47-5 | 265.30 | C14H19NO4 | >98% | 2G | 3800 | chiralix | |
| CX52977-5G | (S)-Boc-beta3-phenylalanine | (S)-3-(tert-butoxycarbonylamino)-3-phenylpropanoicacid | 103365-47-5 | 265.30 | C14H19NO4 | >98% | 5G | 7200 | chiralix | |
| CX79659-1G | (S)-Cbz-beta3-phenylalanine | (S)-3-(benzyloxycarbonylamino)-3-phenylpropanoicacid | 14441-08-8 | 299.32 | C17H17NO4 | >98% | 1G | 2200 | chiralix | |
| CX79659-2G | (S)-Cbz-beta3-phenylalanine | (S)-3-(benzyloxycarbonylamino)-3-phenylpropanoicacid | 14441-08-8 | 299.32 | C17H17NO4 | >98% | 2G | 3800 | chiralix | |
| CX79659-5G | (S)-Cbz-beta3-phenylalanine | (S)-3-(benzyloxycarbonylamino)-3-phenylpropanoicacid | 14441-08-8 | 299.32 | C17H17NO4 | >98% | 5G | 7200 | chiralix | |
| CX56872-1G | (S)-Fmoc-beta3-phenylalanine | (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-phenylpropanoicacid | 209252-15-3 | 387.43 | C24H21NO4 | >98% | 1G | 2600 | chiralix | |
| CX56872-2G | (S)-Fmoc-beta3-phenylalanine | (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-phenylpropanoicacid | 209252-15-3 | 387.43 | C24H21NO4 | >98% | 2G | 4400 | chiralix | |
| CX56872-5G | (S)-Fmoc-beta3-phenylalanine | (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-phenylpropanoicacid | 209252-15-3 | 387.43 | C24H21NO4 | >98% | 5G | 8600 | chiralix | |
| CX44048-1G | Boc-D-tert-leucine | (R)-2-(tert-butoxycarbonylamino)-3,3-dimethylbutanoicacid | 124655-17-0 | 231.29 | C11H21NO4 | Boc-D-tert-Leu-OH | >98% | 1G | 2200 | chiralix |
| CX44048-2G | Boc-D-tert-leucine | (R)-2-(tert-butoxycarbonylamino)-3,3-dimethylbutanoicacid | 124655-17-0 | 231.29 | C11H21NO4 | Boc-D-tert-Leu-OH | >98% | 2G | 3800 | chiralix |
| CX44048-5G | Boc-D-tert-leucine | (R)-2-(tert-butoxycarbonylamino)-3,3-dimethylbutanoicacid | 124655-17-0 | 231.29 | C11H21NO4 | Boc-D-tert-Leu-OH | >98% | 5G | 7200 | chiralix |
| CX22855-1G | Fmoc-D-tert-leucine | (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3,3-dimethylbutanoicacid | 198543-64-5 | 353.41 | C21H23NO4 | Fmoc-D-tert-Leu-OH | >97% | 1G | 2600 | chiralix |
| CX22855-2G | Fmoc-D-tert-leucine | (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3,3-dimethylbutanoicacid | 198543-64-5 | 353.41 | C21H23NO4 | Fmoc-D-tert-Leu-OH | >97% | 2G | 4400 | chiralix |
| CX22855-5G | Fmoc-D-tert-leucine | (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3,3-dimethylbutanoicacid | 198543-64-5 | 353.41 | C21H23NO4 | Fmoc-D-tert-Leu-OH | >97% | 5G | 8600 | chiralix |
| CX28901-1G | (S)-Boc-alpha-methyl-phenylglycine | (S)-2-(tert-butoxycarbonylamino)-2-phenylpropanoicacid | 802541-88-4 | 265.30 | C14H19NO4 | (S)-Boc-Mpg-OH | >98% | 1G | 9000 | chiralix |
| CX28901-2G | (S)-Boc-alpha-methyl-phenylglycine | (S)-2-(tert-butoxycarbonylamino)-2-phenylpropanoicacid | 802541-88-4 | 265.30 | C14H19NO4 | (S)-Boc-Mpg-OH | >98% | 2G | 14800 | chiralix |
| CX28344-1G | (S)-Fmoc-alpha-methyl-phenylglycine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-phenylpropanoicacid | 881921-11-5 | 387.43 | C24H21NO4 | (S)-Fmoc-Mpg-OH | >98% | 1G | 10400 | chiralix |
| CX28344-2G | (S)-Fmoc-alpha-methyl-phenylglycine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-phenylpropanoicacid | 881921-11-5 | 387.43 | C24H21NO4 | (S)-Fmoc-Mpg-OH | >98% | 2G | 17200 | chiralix |
| CX93005-1G | Fmoc-L-azidoalanine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-azidopropanoicacid | 684270-46-0 | 352.34 | C18H16N4O4 | Fmoc-Aza-OH | >98% | 1G | 3400 | chiralix |
| CX93005-5G | Fmoc-L-azidoalanine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-azidopropanoicacid | 684270-46-0 | 352.34 | C18H16N4O4 | Fmoc-Aza-OH | >98% | 5G | 12000 | chiralix |
| CX90286-200MG | bis(N-diazo)-tris(O-acetyl)-2-deoxystreptamine | 4t,6t-diazidocyclohexane-1r,2t,3c-triyltriacetate | 90852-19-0 | 340.29 | C12H16N6O6 | 2-DOSdiazidetriacetate | >98% | 200MG | 4200 | chiralix |
| CX90286-500MG | bis(N-diazo)-tris(O-acetyl)-2-deoxystreptamine | 4t,6t-diazidocyclohexane-1r,2t,3c-triyltriacetate | 90852-19-0 | 340.29 | C12H16N6O6 | 2-DOSdiazidetriacetate | >98% | 500MG | 8800 | chiralix |
| CX90286-1G | bis(N-diazo)-tris(O-acetyl)-2-deoxystreptamine | 4t,6t-diazidocyclohexane-1r,2t,3c-triyltriacetate | 90852-19-0 | 340.29 | C12H16N6O6 | 2-DOSdiazidetriacetate | >98% | 1G | 15200 | chiralix |
| CX44848-200MG | (R)-4-oxopipecolicacidethyleneacetal | (R)-1,4-dioxa-8-azaspiro[4.5]decane-7-carboxylicacid | Notavailable | 187.19 | C8H13NO4 | >98% | 200MG | 5200 | chiralix | |
| CX44848-500MG | (R)-4-oxopipecolicacidethyleneacetal | (R)-1,4-dioxa-8-azaspiro[4.5]decane-7-carboxylicacid | Notavailable | 187.19 | C8H13NO4 | >98% | 500MG | 11000 | chiralix | |
| CX44848-1G | (R)-4-oxopipecolicacidethyleneacetal | (R)-1,4-dioxa-8-azaspiro[4.5]decane-7-carboxylicacid | Notavailable | 187.19 | C8H13NO4 | >98% | 1G | 19200 | chiralix | |
| CX45124-500MG | (R)-alpha-methyl-phenylglycine | (R)-2-amino-2-phenylpropanoicacid | 29738-09-8 | 165.19 | C9H11NO2 | (R)-H-Mpg-OH | >98% | 500MG | 6200 | chiralix |
| CX45124-1G | (R)-alpha-methyl-phenylglycine | (R)-2-amino-2-phenylpropanoicacid | 29738-09-8 | 165.19 | C9H11NO2 | (R)-H-Mpg-OH | >98% | 1G | 10400 | chiralix |
| CX45124-2G | (R)-alpha-methyl-phenylglycine | (R)-2-amino-2-phenylpropanoicacid | 29738-09-8 | 165.19 | C9H11NO2 | (R)-H-Mpg-OH | >98% | 2G | 17200 | chiralix |
| CX43844-1G | L-azidoleucineCHAsalt | cyclohexanaminium(S)-2-azido-4-methylpentanoate | Notavailable | 256.34 | C12H24N4O2 | N3-Leu-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX43844-5G | L-azidoleucineCHAsalt | cyclohexanaminium(S)-2-azido-4-methylpentanoate | Notavailable | 256.34 | C12H24N4O2 | N3-Leu-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX66793-1G | L-azidovalineCHAsalt | cyclohexanaminium(S)-2-azido-3-methylbutanoate | Notavailable | 242.32 | C11H22N4O2 | N3-Val-OH·CHA | >98% | 1G | 2600 | chiralix |
| CX66793-5G | L-azidovalineCHAsalt | cyclohexanaminium(S)-2-azido-3-methylbutanoate | Notavailable | 242.32 | C11H22N4O2 | N3-Val-OH·CHA | >98% | 5G | 9800 | chiralix |
| CX90285-1G | L-azidotryptophanCHAsalt | cyclohexanaminium(S)-2-azido-3-(1H-indol-2-yl)propanoate | Notavailable | 329.40 | C17H23N5O2 | N3-Trp-OH·CHA | >98% | 1G | 2400 | chiralix |
| CX90285-5G | L-azidotryptophanCHAsalt | cyclohexanaminium(S)-2-azido-3-(1H-indol-2-yl)propanoate | Notavailable | 329.40 | C17H23N5O2 | N3-Trp-OH·CHA | >98% | 5G | 9000 | chiralix |
| CX32182-1G | L-azidoalanineCHAsalt | cyclohexanaminium(S)-2-azidopropanoate | Notavailable | 214.26 | C9H18N4O2 | N3-Ala-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX32182-5G | L-azidoalanineCHAsalt | cyclohexanaminium(S)-2-azidopropanoate | Notavailable | 214.26 | C9H18N4O2 | N3-Ala-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX33085-1G | L-azidophenylalanineCHAsalt | cyclohexanaminium(S)-2-azido-3-phenylpropanoate | Notavailable | 290.36 | C15H22N4O2 | N3-Phe-OH·CHA | >98% | 1G | 2400 | chiralix |
| CX33085-5G | L-azidophenylalanineCHAsalt | cyclohexanaminium(S)-2-azido-3-phenylpropanoate | Notavailable | 290.36 | C15H22N4O2 | N3-Phe-OH·CHA | >98% | 5G | 9000 | chiralix |
| CX37236-1G | L-azidoisoleucineCHAsalt | cyclohexanaminium(2S,3S)-2-azido-3-methylpentanoate | Notavailable | 256.34 | C12H24N4O2 | N3-Ile-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX37236-5G | L-azidoisoleucineCHAsalt | cyclohexanaminium(2S,3S)-2-azido-3-methylpentanoate | Notavailable | 256.34 | C12H24N4O2 | N3-Ile-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX81236-1G | L-azidotyrosineCHAsalt | cyclohexanaminium(S)-2-azido-3-(4-hydroxyphenyl)propanoate | Notavailable | 306.36 | C15H22N4O3 | N3-Tyr-OH·CHA | >97% | 1G | 2800 | chiralix |
| CX81236-5G | L-azidotyrosineCHAsalt | cyclohexanaminium(S)-2-azido-3-(4-hydroxyphenyl)propanoate | Notavailable | 306.36 | C15H22N4O3 | N3-Tyr-OH·CHA | >97% | 5G | 10600 | chiralix |
| CX84940-1G | L-azidomethionineCHAsalt | cyclohexanaminium(S)-2-azido-4-(methylthio)butanoate | Notavailable | 274.38 | C11H22N4O2S | N3-Met-OH·CHA | >98% | 1G | 2600 | chiralix |
| CX84940-5G | L-azidomethionineCHAsalt | cyclohexanaminium(S)-2-azido-4-(methylthio)butanoate | Notavailable | 274.38 | C11H22N4O2S | N3-Met-OH·CHA | >98% | 5G | 9800 | chiralix |
| CX81456-200MG | (S)-5-oxopipecolicacidethyleneacetal | (S)-1,4-dioxa-7-azaspiro[4.5]decane-8-carboxylicacid | Notavailable | 187.19 | C8H13NO4 | >98% | 200MG | 5200 | chiralix | |
| CX81456-500MG | (S)-5-oxopipecolicacidethyleneacetal | (S)-1,4-dioxa-7-azaspiro[4.5]decane-8-carboxylicacid | Notavailable | 187.19 | C8H13NO4 | >98% | 500MG | 11000 | chiralix | |
| CX81456-1G | (S)-5-oxopipecolicacidethyleneacetal | (S)-1,4-dioxa-7-azaspiro[4.5]decane-8-carboxylicacid | Notavailable | 187.19 | C8H13NO4 | >98% | 1G | 19200 | chiralix | |
| CX80632-1G | L-azidothreoninetert-butyletherCHAsalt | cyclohexanaminium(2S,3R)-2-azido-3-tert-butoxybutanoate | Notavailable | 300.40 | C14H28N4O3 | N3-Thr(OtBu)-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX80632-5G | L-azidothreoninetert-butyletherCHAsalt | cyclohexanaminium(2S,3R)-2-azido-3-tert-butoxybutanoate | Notavailable | 300.40 | C14H28N4O3 | N3-Thr(OtBu)-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX59871-1G | L-azidoserineCHAsalt | cyclohexanaminium(S)-2-azido-3-hydroxypropanoate | Notavailable | 230.26 | C9H18N4O3 | N3-Ser-OH·CHA | >98% | 1G | 2600 | chiralix |
| CX59871-5G | L-azidoserineCHAsalt | cyclohexanaminium(S)-2-azido-3-hydroxypropanoate | Notavailable | 230.26 | C9H18N4O3 | N3-Ser-OH·CHA | >98% | 5G | 9800 | chiralix |
| CX20625-1G | L-azidoasparticacidmono-tert-butylesterCHAsalt | cyclohexanaminium(S)-2-azido-4-tert-butoxy-4-oxobutanoate | Notavailable | 314.38 | C14H26N4O4 | N3-Asp(OtBu)-OH·CHA | >98% | 1G | 2600 | chiralix |
| CX20625-5G | L-azidoasparticacidmono-tert-butylesterCHAsalt | cyclohexanaminium(S)-2-azido-4-tert-butoxy-4-oxobutanoate | Notavailable | 314.38 | C14H26N4O4 | N3-Asp(OtBu)-OH·CHA | >98% | 5G | 9800 | chiralix |
| CX24163-1G | L-azidoglutamicacidmono-tert-butylesterCHAsalt | cyclohexanaminium(S)-2-azido-5-tert-butoxy-5-oxopentanoate | Notavailable | 328.41 | C15H28N4O4 | N3-Glu(OtBu)-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX24163-5G | L-azidoglutamicacidmono-tert-butylesterCHAsalt | cyclohexanaminium(S)-2-azido-5-tert-butoxy-5-oxopentanoate | Notavailable | 328.41 | C15H28N4O4 | N3-Glu(OtBu)-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX68680-1G | L-azidotyrosinetert-butyletherCHAsalt | cyclohexanaminium(S)-2-azido-3-(4-tert-butoxyphenyl)propanoate | Notavailable | 362.47 | C19H30N4O3 | N3-Tyr(OtBu)-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX68680-5G | L-azidotyrosinetert-butyletherCHAsalt | cyclohexanaminium(S)-2-azido-3-(4-tert-butoxyphenyl)propanoate | Notavailable | 362.47 | C19H30N4O3 | N3-Tyr(OtBu)-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX55921-1G | L-azidoserinetert-butyletherCHAsalt | cyclohexanaminium(S)-2-azido-3-tert-butoxypropanoate | Notavailable | 286.37 | C13H26N4O3 | N3-Ser(OtBu)-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX55921-5G | L-azidoserinetert-butyletherCHAsalt | cyclohexanaminium(S)-2-azido-3-tert-butoxypropanoate | Notavailable | 286.37 | C13H26N4O3 | N3-Ser(OtBu)-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX54776-200MG | (S)-4-oxopipecolicacidethyleneacetal | (S)-1,4-dioxa-8-azaspiro[4.5]decane-7-carboxylicacid | 356073-54-6 | 187.19 | C8H13NO4 | >98% | 200MG | 5200 | chiralix | |
| CX54776-500MG | (S)-4-oxopipecolicacidethyleneacetal | (S)-1,4-dioxa-8-azaspiro[4.5]decane-7-carboxylicacid | 356073-54-6 | 187.19 | C8H13NO4 | >98% | 500MG | 11000 | chiralix | |
| CX54776-1G | (S)-4-oxopipecolicacidethyleneacetal | (S)-1,4-dioxa-8-azaspiro[4.5]decane-7-carboxylicacid | 356073-54-6 | 187.19 | C8H13NO4 | >98% | 1G | 19200 | chiralix | |
| CX46058-1G | D-azidovalineCHAsalt | cyclohexanaminium(R)-2-azido-3-methylbutanoate | Notavailable | 242.32 | C11H22N4O2 | N3-D-Val-OH·CHA | >98% | 1G | 3000 | chiralix |
| CX46058-5G | D-azidovalineCHAsalt | cyclohexanaminium(R)-2-azido-3-methylbutanoate | Notavailable | 242.32 | C11H22N4O2 | N3-D-Val-OH·CHA | >98% | 5G | 11200 | chiralix |
| CX44158-1G | D-azidoalanineCHAsalt | cyclohexanaminium(R)-2-azidopropanoate | Notavailable | 214.26 | C9H18N4O2 | N3-D-Ala-OH·CHA | >98% | 1G | 3400 | chiralix |
| CX44158-5G | D-azidoalanineCHAsalt | cyclohexanaminium(R)-2-azidopropanoate | Notavailable | 214.26 | C9H18N4O2 | N3-D-Ala-OH·CHA | >98% | 5G | 12800 | chiralix |
| CX27954-1G | D-azidophenylalanineCHAsalt | cyclohexanaminium(R)-2-azido-3-phenylpropanoate | Notavailable | 290.36 | C15H22N4O2 | D-N3-Phe-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX27954-5G | D-azidophenylalanineCHAsalt | cyclohexanaminium(R)-2-azido-3-phenylpropanoate | Notavailable | 290.36 | C15H22N4O2 | D-N3-Phe-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX56656-1G | D-azidomethionineCHAsalt | cyclohexanaminium(R)-2-azido-4-(methylthio)butanoate | Notavailable | 274.38 | C11H22N4O2S | N3-D-Met-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX56656-5G | D-azidomethionineCHAsalt | cyclohexanaminium(R)-2-azido-4-(methylthio)butanoate | Notavailable | 274.38 | C11H22N4O2S | N3-D-Met-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX16129-500MG | Cbz-L-bishomopropargylglycineCHAsalt | cyclohexanaminium(S)-2-(benzyloxycarbonylamino)hept-6-ynoate | Notavailable | 374.47 | C21H30N2O4 | Z-Bpg-OH·CHA | >98% | 500MG | 9000 | chiralix |
| CX16129-1G | Cbz-L-bishomopropargylglycineCHAsalt | cyclohexanaminium(S)-2-(benzyloxycarbonylamino)hept-6-ynoate | Notavailable | 374.47 | C21H30N2O4 | Z-Bpg-OH·CHA | >98% | 1G | 14600 | chiralix |
| CX65817-1G | (S)-Cbz-alpha-methyl-phenylglycineCHAsalt | cyclohexanaminium(S)-2-(benzyloxycarbonylamino)-2-phenylpropanoate | Notavailable | 398.50 | C23H30N2O4 | (S)-Cbz-Mpg-OH·CHA | >98% | 1G | 9000 | chiralix |
| CX65817-2G | (S)-Cbz-alpha-methyl-phenylglycineCHAsalt | cyclohexanaminium(S)-2-(benzyloxycarbonylamino)-2-phenylpropanoate | Notavailable | 398.50 | C23H30N2O4 | (S)-Cbz-Mpg-OH·CHA | >98% | 2G | 14800 | chiralix |
| CX19691-500MG | Boc-D-bishomopropargylglycineCHAsalt | cyclohexanaminium(R)-2-(tert-butoxycarbonylamino)hept-6-ynoate | Notavailable | 340.46 | C18H32N2O4 | Boc-D-Bpg-OH·CHA | >98% | 500MG | 9000 | chiralix |
| CX19691-1G | Boc-D-bishomopropargylglycineCHAsalt | cyclohexanaminium(R)-2-(tert-butoxycarbonylamino)hept-6-ynoate | Notavailable | 340.46 | C18H32N2O4 | Boc-D-Bpg-OH·CHA | >98% | 1G | 14600 | chiralix |
| CX59796-500MG | Boc-L-bishomopropargylglycineCHAsalt | cyclohexanaminium(S)-2-(tert-butoxycarbonylamino)hept-6-ynoate | Notavailable | 340.46 | C18H32N2O4 | Boc-Bpg-OH·CHA | >98% | 500MG | 9000 | chiralix |
| CX59796-1G | Boc-L-bishomopropargylglycineCHAsalt | cyclohexanaminium(S)-2-(tert-butoxycarbonylamino)hept-6-ynoate | Notavailable | 340.46 | C18H32N2O4 | Boc-Bpg-OH·CHA | >98% | 1G | 14600 | chiralix |
| CX79723-1G | (R)-Fmoc-alpha-methyl-phenylglycine | (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-phenylpropanoicacid | 881920-86-1 | 387.43 | C24H21NO4 | (R)-Fmoc-Mpg-OH | >98% | 1G | 12000 | chiralix |
| CX79723-2G | (R)-Fmoc-alpha-methyl-phenylglycine | (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-phenylpropanoicacid | 881920-86-1 | 387.43 | C24H21NO4 | (R)-Fmoc-Mpg-OH | >98% | 2G | 19800 | chiralix |
| CX32015-1G | Cbz-D-tert-leucineCHAsalt | cyclohexanaminium(R)-2-(benzyloxycarbonylamino)-3,3-dimethylbutanoate | Notavailable | 364.48 | C20H32N2O4 | Z-D-tert-Leu-OH·CHA | >98% | 1G | 2200 | chiralix |
| CX32015-2G | Cbz-D-tert-leucineCHAsalt | cyclohexanaminium(R)-2-(benzyloxycarbonylamino)-3,3-dimethylbutanoate | Notavailable | 364.48 | C20H32N2O4 | Z-D-tert-Leu-OH·CHA | >98% | 2G | 3800 | chiralix |
| CX32015-5G | Cbz-D-tert-leucineCHAsalt | cyclohexanaminium(R)-2-(benzyloxycarbonylamino)-3,3-dimethylbutanoate | Notavailable | 364.48 | C20H32N2O4 | Z-D-tert-Leu-OH·CHA | >98% | 5G | 7200 | chiralix |
| CX81118-1G | Fmoc-L-azidolysine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-6-azidohexanoicacid | 159610-89-6 | 394.42 | C21H22N4O4 | Fmoc-Lys(N2)-OH | >98% | 1G | 3400 | chiralix |
| CX81118-5G | Fmoc-L-azidolysine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-6-azidohexanoicacid | 159610-89-6 | 394.42 | C21H22N4O4 | Fmoc-Lys(N2)-OH | >98% | 5G | 12000 | chiralix |
| CX19587-500MG | Cbz-D-bishomopropargylglycineCHAsalt | cyclohexanaminium(R)-2-(benzyloxycarbonylamino)hept-6-ynoate | Notavailable | 374.47 | C21H30N2O4 | Z-D-Bpg-OH·CHA | >98% | 500MG | 9000 | chiralix |
| CX19587-1G | Cbz-D-bishomopropargylglycineCHAsalt | cyclohexanaminium(R)-2-(benzyloxycarbonylamino)hept-6-ynoate | Notavailable | 374.47 | C21H30N2O4 | Z-D-Bpg-OH·CHA | >98% | 1G | 14600 | chiralix |
| CX28021-500MG | H-Arg(Boc)2-pNA | (S,E)-tert-butyl(4-amino-5-(4-nitrophenylamino)-5-oxopentylamino)(tert-butoxycarbonylamino)methylenecarbamate | Notavailable | 494.54 | C22H34N6O7 | >97% | 500MG | 6000 | chiralix | |
| CX28021-1G | H-Arg(Boc)2-pNA | (S,E)-tert-butyl(4-amino-5-(4-nitrophenylamino)-5-oxopentylamino)(tert-butoxycarbonylamino)methylenecarbamate | Notavailable | 494.54 | C22H34N6O7 | >97% | 1G | 11000 | chiralix | |
| CX72798-1G | D-azidoasparticacidmono-tert-butylesterCHAsalt | cyclohexanaminium(R)-2-azido-4-tert-butoxy-4-oxobutanoate | Notavailable | 314.38 | C14H26N4O4 | N3-D-Asp(OtBu)-OH·CHA | >98% | 1G | 6200 | chiralix |
| CX72798-5G | D-azidoasparticacidmono-tert-butylesterCHAsalt | cyclohexanaminium(R)-2-azido-4-tert-butoxy-4-oxobutanoate | Notavailable | 314.38 | C14H26N4O4 | N3-D-Asp(OtBu)-OH·CHA | >98% | 5G | 23400 | chiralix |
| CX93516-1G | D-azidoglutamicacidmono-tert-butylesterCHAsalt | cyclohexanaminium(R)-2-azido-5-tert-butoxy-5-oxopentanoate | Notavailable | 328.41 | C15H28N4O4 | N3-D-Glu(OtBu)-OH·CHA | >98% | 1G | 5200 | chiralix |
| CX93516-5G | D-azidoglutamicacidmono-tert-butylesterCHAsalt | cyclohexanaminium(R)-2-azido-5-tert-butoxy-5-oxopentanoate | Notavailable | 328.41 | C15H28N4O4 | N3-D-Glu(OtBu)-OH·CHA | >98% | 5G | 19600 | chiralix |
| CX76762-1G | D-azidoleucineCHAsalt | cyclohexanaminium(R)-2-azido-4-methylpentanoate | Notavailable | 256.34 | C12H24N4O2 | N3-D-Leu-OH·CHA | >98% | 1G | 3000 | chiralix |
| CX76762-5G | D-azidoleucineCHAsalt | cyclohexanaminium(R)-2-azido-4-methylpentanoate | Notavailable | 256.34 | C12H24N4O2 | N3-D-Leu-OH·CHA | >98% | 5G | 11200 | chiralix |
| CX53333-1G | D-azidoisoleucineCHAsalt | cyclohexanaminium(2R,3R)-2-azido-3-methylpentanoate | Notavailable | 256.34 | C12H24N4O2 | N3-D-Ile-OH·CHA | >98% | 1G | 9200 | chiralix |
| CX53333-2G | D-azidoisoleucineCHAsalt | cyclohexanaminium(2R,3R)-2-azido-3-methylpentanoate | Notavailable | 256.34 | C12H24N4O2 | N3-D-Ile-OH·CHA | >98% | 2G | 16400 | chiralix |
| CX83245-1G | D-azidotyrosinetert-butyletherCHAsalt | cyclohexanaminium(R)-2-azido-3-(4-tert-butoxyphenyl)propanoate | Notavailable | 362.47 | C19H30N4O3 | N3-D-Tyr(OtBu)-OH·CHA | >98% | 1G | 5400 | chiralix |
| CX83245-5G | D-azidotyrosinetert-butyletherCHAsalt | cyclohexanaminium(R)-2-azido-3-(4-tert-butoxyphenyl)propanoate | Notavailable | 362.47 | C19H30N4O3 | N3-D-Tyr(OtBu)-OH·CHA | >98% | 5G | 20400 | chiralix |
| CX13425-1G | D-azidoserinetert-butyletherCHAsalt | cyclohexanaminium(R)-2-azido-3-tert-butoxypropanoate | Notavailable | 286.37 | C13H26N4O3 | N3-D-Ser(OtBu)-OH·CHA | >98% | 1G | 7200 | chiralix |
| CX13425-5G | D-azidoserinetert-butyletherCHAsalt | cyclohexanaminium(R)-2-azido-3-tert-butoxypropanoate | Notavailable | 286.37 | C13H26N4O3 | N3-D-Ser(OtBu)-OH·CHA | >98% | 5G | 27200 | chiralix |
| CX29937-1G | D-azidothreoninetert-butyletherCHAsalt | cyclohexanaminium(2R,3S)-2-azido-3-tert-butoxybutanoate | Notavailable | 300.40 | C14H28N4O3 | N3-D-Thr(OtBu)-OH·CHA | >98% | 1G | 6400 | chiralix |
| CX29937-5G | D-azidothreoninetert-butyletherCHAsalt | cyclohexanaminium(2R,3S)-2-azido-3-tert-butoxybutanoate | Notavailable | 300.40 | C14H28N4O3 | N3-D-Thr(OtBu)-OH·CHA | >98% | 5G | 24200 | chiralix |
| CX85233-1G | L-azidothreonineCHAsalt | cyclohexanaminium(2S,3R)-2-azido-3-hydroxybutanoate | Notavailable | 244.29 | C10H20N4O3 | N3-Thr-OH·CHA | >98% | 1G | 2600 | chiralix |
| CX85233-5G | L-azidothreonineCHAsalt | cyclohexanaminium(2S,3R)-2-azido-3-hydroxybutanoate | Notavailable | 244.29 | C10H20N4O3 | N3-Thr-OH·CHA | >98% | 5G | 9800 | chiralix |
| CX37313-1G | D-azidothreonineCHAsalt | cyclohexanaminium(2R,3S)-2-azido-3-hydroxybutanoate | Notavailable | 244.29 | C10H20N4O3 | N3-D-Thr-OH·CHA | >98% | 1G | 3000 | chiralix |
| CX37313-5G | D-azidothreonineCHAsalt | cyclohexanaminium(2R,3S)-2-azido-3-hydroxybutanoate | Notavailable | 244.29 | C10H20N4O3 | N3-D-Thr-OH·CHA | >98% | 5G | 11200 | chiralix |
| CX95405-1G | D-azidoserineCHAsalt | cyclohexanaminium(R)-2-azido-3-hydroxypropanoate | Notavailable | 230.26 | C9H18N4O3 | N3-D-Ser-OH·CHA | >98% | 1G | 3200 | chiralix |
| CX95405-5G | D-azidoserineCHAsalt | cyclohexanaminium(R)-2-azido-3-hydroxypropanoate | Notavailable | 230.26 | C9H18N4O3 | N3-D-Ser-OH·CHA | >98% | 5G | 12000 | chiralix |
| CX57717-1G | L-azidoglutamineDCHAsalt | dicyclohexylammonium(S)-5-amino-2-azido-5-oxopentanoate | Notavailable | 353.46 | C17H31N5O3 | N3-Gln-OH·DCHA | >98% | 1G | 2600 | chiralix |
| CX57717-5G | L-azidoglutamineDCHAsalt | dicyclohexylammonium(S)-5-amino-2-azido-5-oxopentanoate | Notavailable | 353.46 | C17H31N5O3 | N3-Gln-OH·DCHA | >98% | 5G | 9800 | chiralix |
| CX79807-1G | D-azidoglutamineDCHAsalt | dicyclohexylammonium(R)-5-amino-2-azido-5-oxopentanoate | Notavailable | 353.46 | C17H31N5O3 | N3-D-Gln-OH·DCHA | >98% | 1G | 3200 | chiralix |
| CX79807-5G | D-azidoglutamineDCHAsalt | dicyclohexylammonium(R)-5-amino-2-azido-5-oxopentanoate | Notavailable | 353.46 | C17H31N5O3 | N3-D-Gln-OH·DCHA | >98% | 5G | 12000 | chiralix |
| CX94556-1G | L-azidoasparagineDCHAsalt | dicyclohexylammonium(S)-4-amino-2-azido-4-oxobutanoate | 79410-49-4 | 339.43 | C16H29N5O3 | N3-Asn-OH·DCHA | >98% | 1G | 3200 | chiralix |
| CX94556-5G | L-azidoasparagineDCHAsalt | dicyclohexylammonium(S)-4-amino-2-azido-4-oxobutanoate | 79410-49-4 | 339.43 | C16H29N5O3 | N3-Asn-OH·DCHA | >98% | 5G | 12000 | chiralix |
| CX83100-1G | D-azidoasparagineDCHAsalt | dicyclohexylammonium(R)-4-amino-2-azido-4-oxobutanoate | Notavailable | 339.43 | C16H29N5O3 | N3-D-Asn-OH·DCHA | >98% | 1G | 4000 | chiralix |
| CX83100-5G | D-azidoasparagineDCHAsalt | dicyclohexylammonium(R)-4-amino-2-azido-4-oxobutanoate | Notavailable | 339.43 | C16H29N5O3 | N3-D-Asn-OH·DCHA | >98% | 5G | 15000 | chiralix |
| CX48141-1G | D-azidotryptophanCHAsalt | cyclohexanaminium(R)-2-azido-3-(1H-indol-2-yl)propanoate | Notavailable | 329.40 | C17H23N5O2 | N3-D-Trp-OH·CHA | >98% | 1G | 2600 | chiralix |
| CX48141-5G | D-azidotryptophanCHAsalt | cyclohexanaminium(R)-2-azido-3-(1H-indol-2-yl)propanoate | Notavailable | 329.40 | C17H23N5O2 | N3-D-Trp-OH·CHA | >98% | 5G | 9800 | chiralix |
| CX93426-1G | N-im-trityl-L-azidohistidineCHAsalt | cyclohexanaminium(S)-2-azido-3-(1-trityl-1H-imidazol-4-yl)propanoate | Notavailable | 522.64 | C31H34N6O2 | N3-His(Trt)-OH·CHA | >98% | 1G | 4000 | chiralix |
| CX93426-5G | N-im-trityl-L-azidohistidineCHAsalt | cyclohexanaminium(S)-2-azido-3-(1-trityl-1H-imidazol-4-yl)propanoate | Notavailable | 522.64 | C31H34N6O2 | N3-His(Trt)-OH·CHA | >98% | 5G | 15000 | chiralix |
| CX24279-1G | D-azidotyrosineCHAsalt | cyclohexanaminium(R)-2-azido-3-(4-hydroxyphenyl)propanoate | Notavailable | 306.36 | C15H22N4O3 | N3-D-Tyr-OH·CHA | >98% | 1G | 3600 | chiralix |
| CX24279-5G | D-azidotyrosineCHAsalt | cyclohexanaminium(R)-2-azido-3-(4-hydroxyphenyl)propanoate | Notavailable | 306.36 | C15H22N4O3 | N3-D-Tyr-OH·CHA | >98% | 5G | 13600 | chiralix |
| CX78063-1G | L-azido-tert-leucineCHAsalt | cyclohexanaminium(S)-2-azido-3,3-dimethylbutanoate | Notavailable | 256.34 | C12H24N4O2 | N3-tert-Leu-OH·CHA | >98% | 1G | 2800 | chiralix |
| CX78063-5G | L-azido-tert-leucineCHAsalt | cyclohexanaminium(S)-2-azido-3,3-dimethylbutanoate | Notavailable | 256.34 | C12H24N4O2 | N3-tert-Leu-OH·CHA | >98% | 5G | 10600 | chiralix |
| CX30547-1G | D-azido-tert-leucineCHAsalt | cyclohexanaminium(R)-2-azido-3,3-dimethylbutanoate | Notavailable | 256.34 | C12H24N4O2 | N3-D-tert-Leu-OH·CHA | >98% | 1G | 6600 | chiralix |
| CX30547-5G | D-azido-tert-leucineCHAsalt | cyclohexanaminium(R)-2-azido-3,3-dimethylbutanoate | Notavailable | 256.34 | C12H24N4O2 | N3-D-tert-Leu-OH·CHA | >98% | 5G | 25000 | chiralix |
| CX78942-1G | L-azidoallylglycineCHAsalt | cyclohexanaminium(S)-2-azidopent-4-enoate | Notavailable | 240.30 | C11H20N4O2 | N3-Alg-OH·CHA | >98% | 1G | 5600 | chiralix |
| CX78942-5G | L-azidoallylglycineCHAsalt | cyclohexanaminium(S)-2-azidopent-4-enoate | Notavailable | 240.30 | C11H20N4O2 | N3-Alg-OH·CHA | >98% | 5G | 21200 | chiralix |
| CX61332-1G | D-azidoallylglycineCHAsalt | cyclohexanaminium(R)-2-azidopent-4-enoate | Notavailable | 240.30 | C11H20N4O2 | N3-D-Alg-OH·CHA | >98% | 1G | 9000 | chiralix |
| CX61332-2G | D-azidoallylglycineCHAsalt | cyclohexanaminium(R)-2-azidopent-4-enoate | Notavailable | 240.30 | C11H20N4O2 | N3-D-Alg-OH·CHA | >98% | 2G | 16000 | chiralix |
| CX56925-1G | Ng-Pmc-L-azidoarginine | (S)-2-azido-5-(3-(2,2,5,7,8-pentamethylchroman-6-ylsulfonyl)guanidino)pentanoicacid | Notavailable | 466.55 | C20H30N6O5S | Ng-2,2,5,7,8-pentamethylchroman-6-sulfonyl-L-azidoarginine | >95% | 1G | 4000 | chiralix |
| CX56925-5G | Ng-Pmc-L-azidoarginine | (S)-2-azido-5-(3-(2,2,5,7,8-pentamethylchroman-6-ylsulfonyl)guanidino)pentanoicacid | Notavailable | 466.55 | C20H30N6O5S | Ng-2,2,5,7,8-pentamethylchroman-6-sulfonyl-L-azidoarginine | >95% | 5G | 15000 | chiralix |
| CX22361-1G | (S)-azido-alpha-methyl-phenylglycineCHAsalt | cyclohexanaminium(S)-2-azido-2-phenylpropanoate | Notavailable | 290.36 | C15H22N4O2 | (S)-N3-Mpg-OH·CHA | >98% | 1G | 9000 | chiralix |
| CX22361-2G | (S)-azido-alpha-methyl-phenylglycineCHAsalt | cyclohexanaminium(S)-2-azido-2-phenylpropanoate | Notavailable | 290.36 | C15H22N4O2 | (S)-N3-Mpg-OH·CHA | >98% | 2G | 14800 | chiralix |
| CX52265-1G | (R)-azido-alpha-methylphenylglycineCHAsalt | cyclohexanaminium(R)-2-azido-2-phenylpropanoate | Notavailable | 290.36 | C15H22N4O2 | (R)-N3-Mpg-OH·CHA | >98% | 1G | 10400 | chiralix |
| CX52265-2G | (R)-azido-alpha-methylphenylglycineCHAsalt | cyclohexanaminium(R)-2-azido-2-phenylpropanoate | Notavailable | 290.36 | C15H22N4O2 | (R)-N3-Mpg-OH·CHA | >98% | 2G | 17200 | chiralix |
| CX71813-1G | S-Trityl-L-azidocysteineCHAsalt | cyclohexanaminium(R)-2-azido-3-(tritylthio)propanoate | Notavailable | 488.64 | C28H32N4O2S | N3-Cys(Trt)-OH·CHA | >98% | 1G | 3000 | chiralix |
| CX71813-5G | S-Trityl-L-azidocysteineCHAsalt | cyclohexanaminium(R)-2-azido-3-(tritylthio)propanoate | Notavailable | 488.64 | C28H32N4O2S | N3-Cys(Trt)-OH·CHA | >98% | 5G | 11200 | chiralix |
| CX40608-5G | 6-azidohexanoicacid | 6-azidohexanoicacid | 79598-53-1 | 157.17 | C6H11N3O2 | >98% | 5G | 6000 | chiralix | |
| CX40608-10G | 6-azidohexanoicacid | 6-azidohexanoicacid | 79598-53-1 | 157.17 | C6H11N3O2 | >98% | 10G | 11000 | chiralix | |
| CX23053-500MG | (S)-bishomopropargylglycinolhydrochloride | (S)-2-aminohept-6-yn-1-olhydrochloride | Notavailable | 163.65 | C7H14ClNO | >98% | 500MG | 10400 | chiralix | |
| CX23053-1G | (S)-bishomopropargylglycinolhydrochloride | (S)-2-aminohept-6-yn-1-olhydrochloride | Notavailable | 163.65 | C7H14ClNO | >98% | 1G | 17200 | chiralix | |
| CX63523-500MG | (R)-bishomopropargylglycinolhydrochloride | (R)-2-aminohept-6-yn-1-olhydrochloride | Notavailable | 163.65 | C7H14ClNO | >98% | 500MG | 10400 | chiralix | |
| CX63523-1G | (R)-bishomopropargylglycinolhydrochloride | (R)-2-aminohept-6-yn-1-olhydrochloride | Notavailable | 163.65 | C7H14ClNO | >98% | 1G | 17200 | chiralix | |
| CX69091-500MG | (R)-homopropargylglycinolhydrochloride | (R)-2-aminohex-5-yn-1-olhydrochloride | Notavailable | 149.62 | C6H12ClNO | >98% | 500MG | 11000 | chiralix | |
| CX69091-1G | (R)-homopropargylglycinolhydrochloride | (R)-2-aminohex-5-yn-1-olhydrochloride | Notavailable | 149.62 | C6H12ClNO | >98% | 1G | 17800 | chiralix | |
| CX76358-500MG | (S)-homopropargylglycinolhydrochloride | (S)-2-aminohex-5-yn-1-olhydrochloride | Notavailable | 149.62 | C6H12ClNO | >98% | 500MG | 11000 | chiralix | |
| CX76358-1G | (S)-homopropargylglycinolhydrochloride | (S)-2-aminohex-5-yn-1-olhydrochloride | Notavailable | 149.62 | C6H12ClNO | >98% | 1G | 17800 | chiralix | |
| CX55029-2MG | cereulide | cyclo[-Val-D-O-Leu-D-Ala-O-Val-]3 | Notavailable | 1153.40 | C57H96N6O18 | >95% | 2MG | 12000 | chiralix | |
| CX55029-5MG | cereulide | cyclo[-Val-D-O-Leu-D-Ala-O-Val-]3 | Notavailable | 1153.40 | C57H96N6O18 | >95% | 5MG | 24000 | chiralix | |
| CX45120-1G | H-Orn(Boc)-pNA | (S)-tert-butyl(4-amino-5-((4-nitrophenyl)amino)-5-oxopentyl)carbamate | Notavailable | 352.39 | C16H24N4O5 | >98% | 1G | 4000 | chiralix | |
| CX45120-2G | H-Orn(Boc)-pNA | (S)-tert-butyl(4-amino-5-((4-nitrophenyl)amino)-5-oxopentyl)carbamate | Notavailable | 352.39 | C16H24N4O5 | >98% | 2G | 9000 | chiralix | |
| CX45120-5G | H-Orn(Boc)-pNA | (S)-tert-butyl(4-amino-5-((4-nitrophenyl)amino)-5-oxopentyl)carbamate | Notavailable | 352.39 | C16H24N4O5 | >98% | 5G | 15000 | chiralix | |
| CX57163-2MG | 13C6-cereulide | cyclo[-Val-1-13C-D-O-Leu-D-Ala-3-13C-O-Val-]3 | Notavailable | 1159.36 | C5113C6H96N6O18 | >95% | 2MG | 24000 | chiralix | |
| CX64158-1G | Fmoc-Orn-pNA·HCl | (S)-(9H-fluoren-9-yl)methyl(5-ami-((4-nitrophenyl)amino)-1-oxopentan-2-yl)carbamatehydrochloride | Notavailable | 510.97 | C26H27ClN4O5 | Fmoc-Orn-pNAHClsalt | >98% | 1G | 4000 | chiralix |
| CX64158-2G | Fmoc-Orn-pNA·HCl | (S)-(9H-fluoren-9-yl)methyl(5-ami-((4-nitrophenyl)amino)-1-oxopentan-2-yl)carbamatehydrochloride | Notavailable | 510.97 | C26H27ClN4O5 | Fmoc-Orn-pNAHClsalt | >98% | 2G | 7200 | chiralix |
| CX64158-5G | Fmoc-Orn-pNA·HCl | (S)-(9H-fluoren-9-yl)methyl(5-ami-((4-nitrophenyl)amino)-1-oxopentan-2-yl)carbamatehydrochloride | Notavailable | 510.97 | C26H27ClN4O5 | Fmoc-Orn-pNAHClsalt | >98% | 5G | 15000 | chiralix |
| CX80044-250MG | Bis(H-Orn(Boc))-rhodamine110 | Bis(H-Orn(Boc))-rhodamine | Notavailable | 758.86 | C40H50N6O9 | >95% | 250MG | 7600 | chiralix | |
| CX80044-500MG | Bis(H-Orn(Boc))-rhodamine110 | Bis(H-Orn(Boc))-rhodamine | Notavailable | 758.86 | C40H50N6O9 | >95% | 500MG | 14000 | chiralix | |
| CX80044-1G | Bis(H-Orn(Boc))-rhodamine110 | Bis(H-Orn(Boc))-rhodamine | Notavailable | 758.86 | C40H50N6O9 | >95% | 1G | 25000 | chiralix | |
| CX67830-250MG | Bis(H-Arg(Boc)2)-rhodamine110 | Bis(H-Arg(Boc)2)-rhodamine | Notavailable | 1043.17 | C52H70N10O13 | >95% | 250MG | 7800 | chiralix | |
| CX67830-500MG | Bis(H-Arg(Boc)2)-rhodamine110 | Bis(H-Arg(Boc)2)-rhodamine | Notavailable | 1043.17 | C52H70N10O13 | >95% | 500MG | 14400 | chiralix | |
| CX67830-1G | Bis(H-Arg(Boc)2)-rhodamine110 | Bis(H-Arg(Boc)2)-rhodamine | Notavailable | 1043.17 | C52H70N10O13 | >95% | 1G | 26000 | chiralix | |
| CX18326-1G | Fmoc-Orn-AMC·HCl | (S)-(9H-fluoren-9-yl)methyl(5-ami-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxopentan-2-yl)carbamatehydrochloride | Notavailable | 548.03 | C30H30ClN3O5 | >98% | 1G | 5000 | chiralix | |
| CX18326-2G | Fmoc-Orn-AMC·HCl | (S)-(9H-fluoren-9-yl)methyl(5-ami-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxopentan-2-yl)carbamatehydrochloride | Notavailable | 548.03 | C30H30ClN3O5 | >98% | 2G | 9000 | chiralix | |
| CX18326-5G | Fmoc-Orn-AMC·HCl | (S)-(9H-fluoren-9-yl)methyl(5-ami-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxopentan-2-yl)carbamatehydrochloride | Notavailable | 548.03 | C30H30ClN3O5 | >98% | 5G | 19000 | chiralix | |
| CX59077-1G | H-Orn(Boc)-AMC | (S)-tert-butyl(4-amino-5-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-5-oxopentyl)carbamate | Notavailable | 389.45 | C20H27N3O5 | >98% | 1G | 6000 | chiralix | |
| CX59077-2G | H-Orn(Boc)-AMC | (S)-tert-butyl(4-amino-5-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-5-oxopentyl)carbamate | Notavailable | 389.45 | C20H27N3O5 | >98% | 2G | 10800 | chiralix | |
| CX59077-5G | H-Orn(Boc)-AMC | (S)-tert-butyl(4-amino-5-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-5-oxopentyl)carbamate | Notavailable | 389.45 | C20H27N3O5 | >98% | 5G | 22000 | chiralix | |
| CX48623-1G | H-Lys(Boc)-AMC | (S)-tert-butyl(5-amino-6-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-6-oxohexyl)carbamate | 222037-62-9 | 403.47 | C21H29N3O5 | >98% | 1G | 5000 | chiralix | |
| CX48623-2G | H-Lys(Boc)-AMC | (S)-tert-butyl(5-amino-6-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-6-oxohexyl)carbamate | 222037-62-9 | 403.47 | C21H29N3O5 | >98% | 2G | 9000 | chiralix | |
| CX48623-5G | H-Lys(Boc)-AMC | (S)-tert-butyl(5-amino-6-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-6-oxohexyl)carbamate | 222037-62-9 | 403.47 | C21H29N3O5 | >98% | 5G | 19000 | chiralix | |
| CX55361-500MG | H-Arg(Boc)2-AMC | H-Arg(Boc)2-AMC | Notavailable | 531.60 | C26H37N5O7 | >97% | 500MG | 6000 | chiralix | |
| CX55361-1G | H-Arg(Boc)2-AMC | H-Arg(Boc)2-AMC | Notavailable | 531.60 | C26H37N5O7 | >97% | 1G | 10800 | chiralix | |
| CX84944-1G | Fmoc-Lys-AMC·HCl | (S)-(9H-fluoren-9-yl)methyl(6-ami-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxohexan-2-yl)carbamatehydrochloride | Notavailable | 562.06 | C31H32ClN3O5 | >98% | 1G | 4000 | chiralix | |
| CX84944-2G | Fmoc-Lys-AMC·HCl | (S)-(9H-fluoren-9-yl)methyl(6-ami-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxohexan-2-yl)carbamatehydrochloride | Notavailable | 562.06 | C31H32ClN3O5 | >98% | 2G | 7200 | chiralix | |
| CX84944-5G | Fmoc-Lys-AMC·HCl | (S)-(9H-fluoren-9-yl)methyl(6-ami-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxohexan-2-yl)carbamatehydrochloride | Notavailable | 562.06 | C31H32ClN3O5 | >98% | 5G | 15000 | chiralix | |
| CX69359-5G | 4-azidobutyricacid | 4-azidobutanoicacid | 54447-68-6 | 129.12 | C4H7N3O2 | gamma-azidobutyricacid | >98% | 5G | 6000 | chiralix |
| CX69359-10G | 4-azidobutyricacid | 4-azidobutanoicacid | 54447-68-6 | 129.12 | C4H7N3O2 | gamma-azidobutyricacid | >98% | 10G | 11000 | chiralix |
| CX31309-5G | 5-azidovalericacid | 5-azidopentanoicacid | 79583-98-5 | 143.14 | C5H9N3O2 | delta-azidovalericacid | >98% | 5G | 6600 | chiralix |
| CX31309-10G | 5-azidovalericacid | 5-azidopentanoicacid | 79583-98-5 | 143.14 | C5H9N3O2 | delta-azidovalericacid | >98% | 10G | 11800 | chiralix |
| CX98490-5G | 7-azidoheptanoicacid | 7-azidoheptanoicacid | 135920-28-4 | 171.20 | C7H13N3O2 | >98% | 5G | 6000 | chiralix | |
| CX98490-10G | 7-azidoheptanoicacid | 7-azidoheptanoicacid | 135920-28-4 | 171.20 | C7H13N3O2 | >98% | 10G | 11000 | chiralix | |
| CX65527-1G | 6-methylcyclohex-1-enecarboxylicacid | 6-methylcyclohex-1-enecarboxylicacid | 5726-56-7 | 140.18 | C8H12O2 | >98% | 1G | 2800 | chiralix | |
| CX65527-5G | 6-methylcyclohex-1-enecarboxylicacid | 6-methylcyclohex-1-enecarboxylicacid | 5726-56-7 | 140.18 | C8H12O2 | >98% | 5G | 10600 | chiralix | |
| CX65527-10G | 6-methylcyclohex-1-enecarboxylicacid | 6-methylcyclohex-1-enecarboxylicacid | 5726-56-7 | 140.18 | C8H12O2 | >98% | 10G | 17000 | chiralix | |
| CX61074-200MG | (S)-beta2-homoalanineHClsalt | (S)-3-amino-2-methylpropanoicacidhydrochloride | Notavailable | 139.58 | C4H10ClNO2 | (S)-beta2-hAla-OH·HCl | >98% | 200MG | 4800 | chiralix |
| CX61074-500MG | (S)-beta2-homoalanineHClsalt | (S)-3-amino-2-methylpropanoicacidhydrochloride | Notavailable | 139.58 | C4H10ClNO2 | (S)-beta2-hAla-OH·HCl | >98% | 500MG | 9800 | chiralix |
| CX61074-1G | (S)-beta2-homoalanineHClsalt | (S)-3-amino-2-methylpropanoicacidhydrochloride | Notavailable | 139.58 | C4H10ClNO2 | (S)-beta2-hAla-OH·HCl | >98% | 1G | 16000 | chiralix |
| CX39389-200MG | (R)-beta2-homoalanineHClsalt | (R)-3-amino-2-methylpropanoicacidhydrochloride | Notavailable | 139.58 | C4H10ClNO2 | (R)-beta2-hAla-OH·HCl | >98% | 200MG | 4800 | chiralix |
| CX39389-500MG | (R)-beta2-homoalanineHClsalt | (R)-3-amino-2-methylpropanoicacidhydrochloride | Notavailable | 139.58 | C4H10ClNO2 | (R)-beta2-hAla-OH·HCl | >98% | 500MG | 9800 | chiralix |
| CX39389-1G | (R)-beta2-homoalanineHClsalt | (R)-3-amino-2-methylpropanoicacidhydrochloride | Notavailable | 139.58 | C4H10ClNO2 | (R)-beta2-hAla-OH·HCl | >98% | 1G | 16000 | chiralix |
| CX80391-200MG | (R)-beta2-homoleucineHClsalt | (R)-2-(aminomethyl)-4-methylpentanoicacidhydrochloride | Notavailable | 181.66 | C7H16ClNO2 | (R)-beta2-hLeu-OH·HCl | >98% | 200MG | 4800 | chiralix |
| CX80391-500MG | (R)-beta2-homoleucineHClsalt | (R)-2-(aminomethyl)-4-methylpentanoicacidhydrochloride | Notavailable | 181.66 | C7H16ClNO2 | (R)-beta2-hLeu-OH·HCl | >98% | 500MG | 9800 | chiralix |
| CX80391-1G | (R)-beta2-homoleucineHClsalt | (R)-2-(aminomethyl)-4-methylpentanoicacidhydrochloride | Notavailable | 181.66 | C7H16ClNO2 | (R)-beta2-hLeu-OH·HCl | >98% | 1G | 16000 | chiralix |
| CX82876-200MG | (R)-beta2-homovalineHClsalt | (R)-2-(aminomethyl)-3-methylbutanoicacidhydrochloride | Notavailable | 167.63 | C6H14ClNO2 | (R)-beta2-hVal-OH·HCl | >98% | 200MG | 4800 | chiralix |
| CX82876-500MG | (R)-beta2-homovalineHClsalt | (R)-2-(aminomethyl)-3-methylbutanoicacidhydrochloride | Notavailable | 167.63 | C6H14ClNO2 | (R)-beta2-hVal-OH·HCl | >98% | 500MG | 9800 | chiralix |
| CX82876-1G | (R)-beta2-homovalineHClsalt | (R)-2-(aminomethyl)-3-methylbutanoicacidhydrochloride | Notavailable | 167.63 | C6H14ClNO2 | (R)-beta2-hVal-OH·HCl | >98% | 1G | 16000 | chiralix |
| CX93488-1MG | (±)-sorgolactone | (3aR*,8S*,8bS*,2'R*)-3-[(E)-2',5'-dihydro-4'-methyl-5'-oxo-2'-furanyloxymethylene]-8-methyl-3,3a,4,5,6,7,8,8b-octahydroinde,2-b]furan-2-one | Notavailable | 316.35 | C18H20O5 | racemicsorgolactone | >98% | 1MG | 4000 | chiralix |
| CX93488-5MG | (±)-sorgolactone | (3aR*,8S*,8bS*,2'R*)-3-[(E)-2',5'-dihydro-4'-methyl-5'-oxo-2'-furanyloxymethylene]-8-methyl-3,3a,4,5,6,7,8,8b-octahydroinde,2-b]furan-2-one | Notavailable | 316.35 | C18H20O5 | racemicsorgolactone | >98% | 5MG | 15000 | chiralix |
| CX64382-1MG | (±)-strigol | (3aR*,5S*,8bS*,2'R*)-3-[(E)-2',5'-dihydro-4'-methyl-5'-oxo-2'-furanyloxymethylene]-5-hydroxy-8,8-dimethyl-3,3a,4,5,6,7,8,8b-octahydroinde,2-b]furan-2-one | 51820-11-2 | 346.37 | C19H22O6 | >98% | 1MG | 5000 | chiralix | |
| CX64382-5MG | (±)-strigol | (3aR*,5S*,8bS*,2'R*)-3-[(E)-2',5'-dihydro-4'-methyl-5'-oxo-2'-furanyloxymethylene]-5-hydroxy-8,8-dimethyl-3,3a,4,5,6,7,8,8b-octahydroinde,2-b]furan-2-one | 51820-11-2 | 346.37 | C19H22O6 | >98% | 5MG | 18800 | chiralix | |
| CX88057-10MG | Nijmegen-1 | (Z)-methyl2-(1,3-dioxoisoindolin-2-yl)-3-((4-methyl-5-oxo-2,5-dihydrofuran-2-yl)oxy)acrylate | 159155-03-0 | 343.29 | C17H13NO7 | >98% | 10MG | 3600 | chiralix | |
| CX88057-50MG | Nijmegen-1 | (Z)-methyl2-(1,3-dioxoisoindolin-2-yl)-3-((4-methyl-5-oxo-2,5-dihydrofuran-2-yl)oxy)acrylate | 159155-03-0 | 343.29 | C17H13NO7 | >98% | 50MG | 11800 | chiralix | |
| CX42450-200MG | (S)-beta2-homophenylalanineHClsalt | (S)-3-amino-2-benzylpropanoicacidhydrochloride | 1010806-95-7 | 215.68 | C10H14ClNO2 | (S)-beta2-hPhe-OH·HCl | >98% | 200MG | 4800 | chiralix |
| CX42450-500MG | (S)-beta2-homophenylalanineHClsalt | (S)-3-amino-2-benzylpropanoicacidhydrochloride | 1010806-95-7 | 215.68 | C10H14ClNO2 | (S)-beta2-hPhe-OH·HCl | >98% | 500MG | 9800 | chiralix |
| CX42450-1G | (S)-beta2-homophenylalanineHClsalt | (S)-3-amino-2-benzylpropanoicacidhydrochloride | 1010806-95-7 | 215.68 | C10H14ClNO2 | (S)-beta2-hPhe-OH·HCl | >98% | 1G | 16000 | chiralix |
| CX35419-200MG | (S)-beta2-homovalineHClsalt | (S)-2-(aminomethyl)-3-methylbutanoicacidhydrochloride | Notavailable | 167.63 | C6H14ClNO2 | (S)-beta2-hVal-OH·HCl | >98% | 200MG | 4800 | chiralix |
| CX35419-500MG | (S)-beta2-homovalineHClsalt | (S)-2-(aminomethyl)-3-methylbutanoicacidhydrochloride | Notavailable | 167.63 | C6H14ClNO2 | (S)-beta2-hVal-OH·HCl | >98% | 500MG | 9800 | chiralix |
| CX35419-1G | (S)-beta2-homovalineHClsalt | (S)-2-(aminomethyl)-3-methylbutanoicacidhydrochloride | Notavailable | 167.63 | C6H14ClNO2 | (S)-beta2-hVal-OH·HCl | >98% | 1G | 16000 | chiralix |
| CX11583-200MG | (R)-beta2-homophenylalanineHClsalt | (R)-3-amino-2-benzylpropanoicacidhydrochloride | Notavailable | 215.68 | C10H14ClNO2 | (R)-beta2-hPhe-OH·HCl | >98% | 200MG | 4800 | chiralix |
| CX11583-500MG | (R)-beta2-homophenylalanineHClsalt | (R)-3-amino-2-benzylpropanoicacidhydrochloride | Notavailable | 215.68 | C10H14ClNO2 | (R)-beta2-hPhe-OH·HCl | >98% | 500MG | 9800 | chiralix |
| CX11583-1G | (R)-beta2-homophenylalanineHClsalt | (R)-3-amino-2-benzylpropanoicacidhydrochloride | Notavailable | 215.68 | C10H14ClNO2 | (R)-beta2-hPhe-OH·HCl | >98% | 1G | 16000 | chiralix |
| CX92224-200MG | (S)-beta2-homoleucineHClsalt | (S)-2-(aminomethyl)-4-methylpentanoicacidhydrochloride | Notavailable | 181.66 | C7H16ClNO2 | (S)-beta2-hLeu-OH·HCl | >98% | 200MG | 4800 | chiralix |
| CX92224-500MG | (S)-beta2-homoleucineHClsalt | (S)-2-(aminomethyl)-4-methylpentanoicacidhydrochloride | Notavailable | 181.66 | C7H16ClNO2 | (S)-beta2-hLeu-OH·HCl | >98% | 500MG | 9800 | chiralix |
| CX92224-1G | (S)-beta2-homoleucineHClsalt | (S)-2-(aminomethyl)-4-methylpentanoicacidhydrochloride | Notavailable | 181.66 | C7H16ClNO2 | (S)-beta2-hLeu-OH·HCl | >98% | 1G | 16000 | chiralix |
| CX81018-500MG | (S)-Fmoc-beta2-homoalanine | (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropanoicacid | 203854-58-4 | 325.36 | C19H19NO4 | (S)-Fmoc-beta2-hAla-OH | >98% | 500MG | 11200 | chiralix |
| CX81018-1G | (S)-Fmoc-beta2-homoalanine | (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropanoicacid | 203854-58-4 | 325.36 | C19H19NO4 | (S)-Fmoc-beta2-hAla-OH | >98% | 1G | 18400 | chiralix |
| CX85919-500MG | (R)-Fmoc-beta2-homoalanine | (R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropanoicacid | Notavailable | 325.36 | C19H19NO4 | (R)-Fmoc-beta2-hAla-OH | >98% | 500MG | 11200 | chiralix |
| CX85919-1G | (R)-Fmoc-beta2-homoalanine | (R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropanoicacid | Notavailable | 325.36 | C19H19NO4 | (R)-Fmoc-beta2-hAla-OH | >98% | 1G | 18400 | chiralix |
| CX98774-500MG | (R)-Fmoc-beta2-homoleucine | (R)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)-4-methylpentanoicacid | 1018899-99-4 | 367.44 | C22H25NO4 | (R)-Fmoc-beta2-hLeu-OH | >98% | 500MG | 11200 | chiralix |
| CX98774-1G | (R)-Fmoc-beta2-homoleucine | (R)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)-4-methylpentanoicacid | 1018899-99-4 | 367.44 | C22H25NO4 | (R)-Fmoc-beta2-hLeu-OH | >98% | 1G | 18400 | chiralix |
| CX33604-500MG | (R)-Fmoc-beta2-homovaline | (R)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)-3-methylbutanoicacid | Notavailable | 353.41 | C21H23NO4 | (R)-Fmoc-beta2-hVal-OH | >98% | 500MG | 11200 | chiralix |
| CX33604-1G | (R)-Fmoc-beta2-homovaline | (R)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)-3-methylbutanoicacid | Notavailable | 353.41 | C21H23NO4 | (R)-Fmoc-beta2-hVal-OH | >98% | 1G | 18400 | chiralix |
| CX82946-500MG | (S)-Fmoc-beta2-homophenylalanine | (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-benzylpropanoicacid | 203854-62-0 | 401.45 | C25H23NO4 | (S)-Fmoc-beta2-hPhe-OH | >98% | 500MG | 11200 | chiralix |
| CX82946-1G | (S)-Fmoc-beta2-homophenylalanine | (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-benzylpropanoicacid | 203854-62-0 | 401.45 | C25H23NO4 | (S)-Fmoc-beta2-hPhe-OH | >98% | 1G | 18400 | chiralix |
| CX86231-500MG | (S)-Fmoc-beta2-homovaline | (S)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)-3-methylbutanoicacid | 203854-59-5 | 353.41 | C21H23NO4 | (S)-Fmoc-beta2-hVal-OH | >98% | 500MG | 11200 | chiralix |
| CX86231-1G | (S)-Fmoc-beta2-homovaline | (S)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)-3-methylbutanoicacid | 203854-59-5 | 353.41 | C21H23NO4 | (S)-Fmoc-beta2-hVal-OH | >98% | 1G | 18400 | chiralix |
| CX15046-500MG | (R)-Fmoc-beta2-homophenylalanine | (R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-benzylpropanoicacid | 828254-16-6 | 401.45 | C25H23NO4 | (R)-Fmoc-beta2-hPhe-OH | >98% | 500MG | 11200 | chiralix |
| CX15046-1G | (R)-Fmoc-beta2-homophenylalanine | (R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-benzylpropanoicacid | 828254-16-6 | 401.45 | C25H23NO4 | (R)-Fmoc-beta2-hPhe-OH | >98% | 1G | 18400 | chiralix |
| CX30199-500MG | (S)-Fmoc-beta2-homoleucine | (S)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)-4-methylpentanoicacid | 193887-45-5 | 367.44 | C22H25NO4 | (S)-Fmoc-beta2-hLeu-OH | >98% | 500MG | 11200 | chiralix |
| CX30199-1G | (S)-Fmoc-beta2-homoleucine | (S)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)methyl)-4-methylpentanoicacid | 193887-45-5 | 367.44 | C22H25NO4 | (S)-Fmoc-beta2-hLeu-OH | >98% | 1G | 18400 | chiralix |
| CX20422-1ML | cereulide(50µg/mLinacetonitrile) | cyclo[-Val-D-O-Leu-D-Ala-O-Val-]3(50µg/mLinacetonitrile) | Notavailable | 1153.40 | C57H96N6O18 | cereulidestocksolution | >95% | 1ML | 5000 | chiralix |
| CX87778-1ML | 13C6-cereulide(20µg/mLinacetonitrile) | cyclo[-Val-1-13C-D-O-Leu-D-Ala-3-13C-O-Val-]3(20µg/mLinacetonitrile) | Notavailable | 1159.36 | C5113C6H96N6O18 | 13C6-cereulidestocksolution | >95% | 1ML | 5000 | chiralix |
| CX18112-1G | 4-(azidomethyl)benzoicacid | 4-(azidomethyl)benzoicacid | 79584-03-5 | 177.16 | C8H7N3O2 | >98% | 1G | 3000 | chiralix | |
| CX18112-5G | 4-(azidomethyl)benzoicacid | 4-(azidomethyl)benzoicacid | 79584-03-5 | 177.16 | C8H7N3O2 | >98% | 5G | 7400 | chiralix | |
| CX18112-10G | 4-(azidomethyl)benzoicacid | 4-(azidomethyl)benzoicacid | 79584-03-5 | 177.16 | C8H7N3O2 | >98% | 10G | 13200 | chiralix | |
| CX95981-5G | 2,2,2-trichloroethoxysulfonylchloride | 2,2,2-trichloroethoxysulfonylchloride | 764-09-0 | 247.91 | C2H2Cl4O2S | chlorosulfuricacid2,2,2-trichloroethylester | >98% | 5G | 2200 | chiralix |
| CX95981-10G | 2,2,2-trichloroethoxysulfonylchloride | 2,2,2-trichloroethoxysulfonylchloride | 764-09-0 | 247.91 | C2H2Cl4O2S | chlorosulfuricacid2,2,2-trichloroethylester | >98% | 10G | 4000 | chiralix |
| CX95981-25G | 2,2,2-trichloroethoxysulfonylchloride | 2,2,2-trichloroethoxysulfonylchloride | 764-09-0 | 247.91 | C2H2Cl4O2S | chlorosulfuricacid2,2,2-trichloroethylester | >98% | 25G | 8400 | chiralix |
| CX62483-1G | 2-(azidomethyl)benzoicacid | 2-(azidomethyl)benzoicacid | 289712-57-8 | 177.16 | C8H7N3O2 | >98% | 1G | 4200 | chiralix | |
| CX62483-2G | 2-(azidomethyl)benzoicacid | 2-(azidomethyl)benzoicacid | 289712-57-8 | 177.16 | C8H7N3O2 | >98% | 2G | 7600 | chiralix | |
| CX62483-5G | 2-(azidomethyl)benzoicacid | 2-(azidomethyl)benzoicacid | 289712-57-8 | 177.16 | C8H7N3O2 | >98% | 5G | 16000 | chiralix | |
| CX80461-1G | 3-(azidomethyl)benzoicacid | 3-(azidomethyl)benzoicacid | 905973-32-2 | 177.16 | C8H7N3O2 | >98% | 1G | 4200 | chiralix | |
| CX80461-2G | 3-(azidomethyl)benzoicacid | 3-(azidomethyl)benzoicacid | 905973-32-2 | 177.16 | C8H7N3O2 | >98% | 2G | 7600 | chiralix | |
| CX80461-5G | 3-(azidomethyl)benzoicacid | 3-(azidomethyl)benzoicacid | 905973-32-2 | 177.16 | C8H7N3O2 | >98% | 5G | 16000 | chiralix | |
| CX27597-1G | 2,3-dimethyl-1-(2,2,2-trichloroethoxysulfuryl)imidazoliumtriflate | 2,3-dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-iumtrifluoromethanesulfonate | 1185733-70-3 | 457.66 | C8H10Cl3F3N2O6S2 | >98% | 1G | 2600 | chiralix | |
| CX27597-5G | 2,3-dimethyl-1-(2,2,2-trichloroethoxysulfuryl)imidazoliumtriflate | 2,3-dimethyl-1-((2,2,2-trichloroethoxy)sulfonyl)-1H-imidazol-3-iumtrifluoromethanesulfonate | 1185733-70-3 | 457.66 | C8H10Cl3F3N2O6S2 | >98% | 5G | 9800 | chiralix | |
| CX50506-10MG | TIS108 | 6-phenoxy-1-phenyl-2-(1H-1,2,4-triazol-1-yl)hexan-1-one | Notavailable | 335.40 | C20H21N3O2 | >98% | 10MG | 3600 | chiralix | |
| CX50506-50MG | TIS108 | 6-phenoxy-1-phenyl-2-(1H-1,2,4-triazol-1-yl)hexan-1-one | Notavailable | 335.40 | C20H21N3O2 | >98% | 50MG | 13800 | chiralix | |
| CX50506-100MG | TIS108 | 6-phenoxy-1-phenyl-2-(1H-1,2,4-triazol-1-yl)hexan-1-one | Notavailable | 335.40 | C20H21N3O2 | >98% | 100MG | 23000 | chiralix | |
| CX95469-10MG | 4-Brdebranone | 5-(4-bromophenoxy)-3-methylfuran-2(5H)-one | 1332863-94-1 | 269.09 | C11H9BrO3 | 4BD | >98% | 10MG | 3000 | chiralix |
| CX95469-50MG | 4-Brdebranone | 5-(4-bromophenoxy)-3-methylfuran-2(5H)-one | 1332863-94-1 | 269.09 | C11H9BrO3 | 4BD | >98% | 50MG | 11400 | chiralix |
| CX95469-100MG | 4-Brdebranone | 5-(4-bromophenoxy)-3-methylfuran-2(5H)-one | 1332863-94-1 | 269.09 | C11H9BrO3 | 4BD | >98% | 100MG | 19600 | chiralix |
| CX75854-10MG | 4-CNdebranone | 5-(4-cyanophenoxy)-3-methylfuran-2(5H)-one | 1332863-97-4 | 215.20 | C12H9NO3 | >98% | 10MG | 3000 | chiralix | |
| CX75854-50MG | 4-CNdebranone | 5-(4-cyanophenoxy)-3-methylfuran-2(5H)-one | 1332863-97-4 | 215.20 | C12H9NO3 | >98% | 50MG | 11400 | chiralix | |
| CX75854-100MG | 4-CNdebranone | 5-(4-cyanophenoxy)-3-methylfuran-2(5H)-one | 1332863-97-4 | 215.20 | C12H9NO3 | >98% | 100MG | 19600 | chiralix | |
| CX52612-10MG | Abamineoxalicacidsalt | (E)-3-(3,4-dimethoxyphenyl)-N-(4-fluorobenzyl)-N-(2-methoxy-2-oxoethyl)prop-2-en-1-aminiumcarboxyformate | Notavailable | 463.45 | C23H26FNO8 | >98% | 10MG | 3000 | chiralix | |
| CX52612-50MG | Abamineoxalicacidsalt | (E)-3-(3,4-dimethoxyphenyl)-N-(4-fluorobenzyl)-N-(2-methoxy-2-oxoethyl)prop-2-en-1-aminiumcarboxyformate | Notavailable | 463.45 | C23H26FNO8 | >98% | 50MG | 11400 | chiralix | |
| CX52612-100MG | Abamineoxalicacidsalt | (E)-3-(3,4-dimethoxyphenyl)-N-(4-fluorobenzyl)-N-(2-methoxy-2-oxoethyl)prop-2-en-1-aminiumcarboxyformate | Notavailable | 463.45 | C23H26FNO8 | >98% | 100MG | 19600 | chiralix | |
| CX93797-10G | Fmoc-D-cyclohexylglycine | (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-cyclohexylaceticacid | 198543-96-3 | 379.45 | C23H25NO4 | Fmoc-D-Chg-OH | >97% | 10G | 6000 | chiralix |
| CX93797-25G | Fmoc-D-cyclohexylglycine | (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-cyclohexylaceticacid | 198543-96-3 | 379.45 | C23H25NO4 | Fmoc-D-Chg-OH | >97% | 25G | 13000 | chiralix |
| CX29693-10G | Fmoc-L-cyclohexylglycine | (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-cyclohexylaceticacid | 161321-36-4 | 379.45 | C23H25NO4 | Fmoc-L-Chg-OH | >97% | 10G | 6000 | chiralix |
| CX29693-25G | Fmoc-L-cyclohexylglycine | (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-cyclohexylaceticacid | 161321-36-4 | 379.45 | C23H25NO4 | Fmoc-L-Chg-OH | >97% | 25G | 13000 | chiralix |
公司主要产品：
1、氨基酸类：包括各种以氨基酸为骨架的手性衍生物。
2、N-BOC保护的氨基酸骨架类
3、N-CBZ 保护的氨基酸骨架类
4、N-FMOC 保护的氨基酸骨架类
5、AZIDO氨基酸骨架类
6、β2氨基酸骨架类
7、FMOC保护的β2氨基酸骨架类
8、CHROMOGENIC 及FLUOROGENIC氨基酸
9、氨基乙醇及其衍生产品
10、CEREULIDE & 13C6-CEREULIDE（致吐毒素及其衍生品）
11、STRIGOLACTONES & ANALOGUES（独脚金内酯及其类似物）
12、其它产品
更多产品请访问：http://www.chiralix.com/
世界*实验材料供应商Chiralix正式授权上海金山科研平台为其中国代理，Chiralix在一直是行业的*,一直为广大科研客户提供zui为优质的产品和服务,上海金山科研平台一直秉承为中国科研客户带来的产品，的服务，签约Chiralix就是为了给广大科研客户带来更加完善的产品和服务
Chiralix中国代理，Chiralix上海代理，Chiralix北京代理，Chiralix广东代理，Chiralix江苏代理Chiralix湖北代理,Chiralix天津,Chiralix黑龙江代理,Chiralix内蒙古代理,Chiralix吉林代理,Chiralix福建代理,Chiralix江苏代理,Chiralix浙江代理,Chiralix四川代理,
我们公司zui大优势是强大的采购，
1：基本什么都能进口，血清，抗体，耗材，还有部分限制进口的，
2：货品全，现经营过700多个品牌，基本所有生物试剂耗材都可以进口，特别是冷偏的产品那就更有优势，
3：提供加急服务，一般1-2周到货，超过时限加急费全免
4：价格公道，绝大部分价格有优势，当然不能保证100%产品都是,因为意味着没有服务.
5：良好的信誉，大部分客户我们提供货到付款服务，客户包括清华，北大交大复旦，中山等100多所大学，ROCHE，阿斯利康，国药，fisher等500多家公司
6：我们还是santa,AdvancedBiotechnologiesInc;AthensResearch&Technology,bangs,BBInternational,crystalchem,dianova,FDNeurotechnologies,Inc.FormuMaxScientific,Inc;Genebridege;GlycotopeBiotechnologyGmbH;iduron;InnovativeResearchofAmerica；Ludger；neuroprobe;omicronbio;Polysciences;prospecbi;QA-BIO；quickzyme；RESEARCHDIETS,INC；sterlitech；sysy；TriLinkBioTechnologies,Inc；worthington-biochem;zyagen;......几十家国外公司授权代理
7：我们还从事invitrogen，qiagen;abcam;sigma;neb;roche;merck;rnd;BD;GE;pierce;BioLegend....等*批发
© 金山科研平台是专业的授权总代理区域代理经销平台。
© 如需询价，请加客服QQ：1749072012 、客服微信：jinshanbio，或发送邮件到1749072012@qq.com
© 平台为生命科学研究相关领域提供一站式耗材试剂仪器解决方案和采购服务，数据资源基于CC协议。
© 本文地址：https://16ao.com/thread-219166.htm
© Chiralix 2015，产品报价联系微信jinshanbio
© 如需询价，请加客服QQ：1749072012 、客服微信：jinshanbio，或发送邮件到1749072012@qq.com
© 平台为生命科学研究相关领域提供一站式耗材试剂仪器解决方案和采购服务，数据资源基于CC协议。
© 本文地址：https://16ao.com/thread-219166.htm
© Chiralix 2015，产品报价联系微信jinshanbio
特别声明：以上内容(如有图片亦包括在内)来源于授权厂家或网络，如有侵权，请联系删除，本平台不提供信息存储服务。
Notice: The content above (including the pictures if any)comes from authorized manufacturers or networks. In case of infringement, please contact to delete it. This platform does not provide information storage services.
产品询价需求提交
猜你喜欢：
Bioworld巴傲得货号：BS22018100ul
2025-07-22
BD IS代理644244 Ratiometric Calcium Assay Kit
2025-06-24
Pierce代理PA517021 ANTI-DICER EA
2025-06-23
岛津SPLING,GLASS COLUMN JOINT
2024-07-22
产品询价请加微信：jinshanbio
扫码添加客服微信，咨询产品报价
QQ:1749072012 为你推荐：